Computational Postdoctoral Fellow
We have an opportunity for a postdoctoral fellow to join us under the leadership of Dr Ana Cvejic (Wellcome Sanger Institute) and Peter Campbell (WSI) as part of the Open Targets program.
Open Targets aims to provide evidence on the biological validity of therapeutic targets and provide an initial assessment of the likely effectiveness of pharmacological intervention on these targets, using genome-scale experiments and analysis. This pioneering public-private partnership between Sanofi, Celgene, EMBL-EBI, GlaxoSmithKline, and the Wellcome Sanger Institute, aims to provide a R&D framework that applies to all aspects of human disease, and to share its data openly with the scientific community (http://www.opentargets.org).
About the Role:
In this project, you will analyse newly generated single cell (scRNA-Seq and scATAC-Seq) as well as novel and spatial transcriptomics data sets (In Situ Sequencing and 10x Visium) to understand the molecular properties of immune cells infiltrating tumour sites. The underlying data sets comprise thousands of unique molecular signals measured for tens of thousands of cells or physical locations in each tumour. You will employ methods from high dimensional and spatial statistics, and machine learning, to chart and understand the nature of different tumour-associated immune cells, how they interact and change biological functions and how the underlying molecular changes could be exploited as therapeutic targets.
You will have a PhD in Bioinformatics, Computational Biology, Biostatistics or in a related quantitative field (e.g. Mathematics, Physics, Statistics). You will be passionate about science, hardworking, and excited to learn and improve your skills in an outstanding and supportive research environment. You will be part of a multidisciplinary team and will be tasked with proactively seeking and maintaining appropriate collaborations. You will also be expected to drive forward the project, working closely with biologists, clinicians and bioinformaticians within and outside the group to accomplish scientific objectives.
- A PhD in Bioinformatics, Computational Biology, Biostatistics or in a related quantitative field (e.g. Mathematics, Physics, Statistics), and a passion for problem solving
- Extensive experience in a research environment with a well-established publication track record
- Formal and extensive training in mathematical and statistical analysis of complex data sets
- An understanding, experience and published outcomes from analysing and interpreting large datasets using at least one statistical package (e.g. R/SPLUS, SAS) and experience in programming (e.g. Perl, Python, C++, Java). Python experience is an advantage.
Behaviours and Competencies:
- The ability to effectively communicate with collaborators and occasionally present oral communication to large groups
- Proven independent working style, technical problem solving, data analysis and generation of novel ideas
- Demonstrates inclusivity and respect for all
- Training in statistical methods appropriate for biological research
- Experience in genomics and transcriptomics approaches (phylogenetics, SNP analysis, single-cell RNA-sequencing), and in method development
- Experience in implementation of machine learning techniques (e.g. linear/non-linear classification, ensemble learning, neural networks, Bayesian/variational inference/MCMC, clustering and dimensionality reduction)
- Experience in single-cell multiomics analysis in Python and/or R e.g. analysis with ScanPy in Python and/or Seurat in R
- Experience in image analysis
Please apply with your CV and a cover letter outlining your suitability for the role addressing the criteria set out above and in the job description.
About Open Targets
Open Targets is a pioneering public-private partnership between European Bioinformatics Institute (EMBL-EBI), GlaxoSmithKline (GSK), the Wellcome Sanger Institute (Sanger), Sanofi and Bristol Meyers Squibb (BMS), located at the Wellcome Genome Campus in Hinxton, near Cambridge, UK.
Open Targets brings together expertise from five complementary institutions to generate evidence on the biological validity of therapeutic targets and provide an initial assessment of the likely effectiveness of pharmacological intervention on these targets, using genome-scale experiments and analysis. Open Targets aims to provide an R&D framework that applies to all aspects of human disease to improve the success rate of discovering new medicines and share data openly in the interest of accelerating drug discovery.